Zentalis' Azenosertib Advances: FDA Aligns on Phase 3, DENALI Readout Expected for Accelerated Approval
ZNTL has more than doubled off its 52-week low of $1.01 on light trading volume (0.3× avg).
Summary
Zentalis Pharmaceuticals announced its full-year 2025 financial results and significant operational advancements for its lead oncology asset, azenosertib. The company completed enrollment for DENALI Part 2a, a registration-intended study, and achieved alignment with the FDA on the design for its Phase 3 ASPENOVA confirmatory trial for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Critically, Zentalis anticipates topline data from the DENALI Part 2 trial by year-end 2026, which could potentially support accelerated approval. Financially, the company reported a strong cash position of $245.9 million as of December 31, 2025, extending its cash runway into late 2027, well beyond the anticipated DENALI readout. This comprehensive update provides significant de-risking for the lead program and offers substantial financial stability, making 2026 a pivotal year for the company. Investors should closely watch for the DENALI Part 2 readout and the initiation of the ASPENOVA trial in the first half of 2026.
At the time of this announcement, ZNTL was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.9M. The 52-week trading range was $1.01 to $3.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.